natgillin/translations-raw huggingface dataset:
The subject matter of claim 13, wherein the excluded E1a isoform is E1a-12S or E1a-13S. 
Predmetni sadržaj prema zahtjevu 13, gdje je isključena Ela izoforma E1a-12S ili Ela-13S.
After cooling to room temperature water (142 ml) was added and the solution extracted with ether (440 ml), dried over anhydrous magnesium sulphate and after filtration, concentrated under reduced pressure. 
Nakon hlađenja na sobnu temperaturu, doda se voda (142 ml) 1 otopina se ekstrahira eterom (440 ml), suši iznad anhidridnog magnezij sulfata 1 nakon filtriranja, koncentrira se uz smanjeni tlak.
• wood shavings obtained from pine or fir wood, said shavings having sizes within a range from 1-50 mm, preferably 5-20 mm; 
• piljevinu dobivenu od bora ili jelovine, navedena piljevina bivajući veličine u rasponu od 1 – 50 mm, poželjno 5 – 20 mm;
The method as claimed in any one of the preceding claims, wherein the method further comprises the step of applying a balancing layer (4) on the other side of the core (3), before applying heat and pressure, to obtain a balancing layer. 
Metoda u skladu sa bilo kojim od prethodnih patentnih zahtjeva, gdje metoda dalje sadrži korak nanošenja balansirajućeg sloja (4) na drugu stranu jezgre (3), prije primjene topline 1 pritiska, da bi se dobio balansirajući sloj.
The monohydrate was even further characterized by the d-spacings of 5.85, 5.21, and 3.52 angstroms. 
Monohidrat je nadalje karakteriziran d-razmacima od 5.85, 5.21, i 3.52 angstr&ma.
is hydrogen; (C1-C4)alkyl optionally substituted with a hydroxy group or a (C1-C4)alkoxy group; or (C3-C8)cycloalkyl; 
R' je vodik; (Ci-Cqy)alkil koji može biti supstituiran s hidroksilnom skupinom ili (C,-Cqy)alkoksilnom skupinom; ili (C3-Cg)cikloalkil;
The pharmaceutical composition according to claim 5, for the treatment of Alzheimer's disease, depression, and schizophrenia. 
Farmaceutski pripravak prema zahtjevu 5, naznačen time da nadalje sadrži terapeutski učinkovitu količinu inhibitora ponovne pohrane 5-HTÂ«, melatonin, melatoninergijski modulator ili njihovu farmaceutski prihvatljivu sol.
Use of a compound selected from neramexane, its optical isomers, diastereoisomers, polymorphs, enantiomers, hydrates, pharmaceutically acceptable salts and mixtures thereof as an antimicrobial compound in an aqueous based pharmaceutical composition comprising an aqueous vehicle, wherein the composition is preservative free or wherein the composition further comprises a preservative, wherein the concentration of the preservative is less than the concentration required to effectively preserve the corresponding placebo composition according to the USP<51 > preservative efficacy test. 
Uporaba nerameksana, naznačena time, da se koristi kao antimikrobno sredstvo u sastavu bez konzervansa na bazi vode za farmaceutsku uporabu, dok spomenuti sastav sadrži vodeni nosač i aktivni sastojak odabran od spomenutog nerameksana, njegovih optičkih izomera, diastereomera, polimorfa, enantiomera, hidrata, farmaceutski prihvatljivih soli i mješavina bilo kojega od prethodnih.
A process for the preparation of a compound of general formula (I): 
Postupak dobivanja spoja opće formule (I):
Data from PI hydrolysis assay are plotted using non-linear least square regression by the Prism program (Graphpad, GraphPad Software, San Diego, Calif.), from which dose ratio is also calculated. 
Za podatkc iz ispitivanja hidrolize PI načinjen je grafički prikaz pomoću nclincarnc regresija najmanjih kvadrata, programom Prism (Graphpad, GraphPad Software, San Diego, CA), a iz toga je izračunat i odnos doza.
The pharmaceutical composition for use of claim 1 or 2, wherein the patient experiences an improvement in forced expiratory volume in one second (FEV1) for at least 15 days after the administration period ends, as compared to the FEV1 of the patient prior to treatment. 
Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1 ili 2, naznačen time, što kod pacijenta dolazi do poboljšanja volumena prisilnog izdisanja u jednoj sekundi (FEV;) tokom najmanje 15 dana nakon završetka perioda primijene, u usporedbi sa FEY; pacijenta prije liječenja.
The process of claim 1, wherein the solution of hydrobromic acid in acetic acid comprises less than 0.5% of free bromine and less than 1000 ppm of metal ion impurities. 
Glatiramer acetat, naznačen time, da nema više od 0,1% bromiranog tirozina i da ima manje od 1000 ppm nečistoća metalnim ionima.
A process according to claim 2, wherein said enantioselectively reducing is carried out in a solvent selected from the group consisting of water, methanol, ethanol, isopropanol, n-butanol, t-butanol, dimethyl formamide, dimethyl acetamide, N-methyl pyrrolidone, toluene, benzene, xylene, THF, dioxane, 2-methoxyethyl ether, diethyl ether, isopropyl ether, t-butyl methyl ether, ethyl acetate, isopropyl acetate, acetonitrile, and mixtures thereof. 
Postupak prema patentnom zahtjevu 17 naznačeno time da je enantioselektivna redukcija provedena u otapalu odabranom iz skupine koju čine voda, metanol, etanol, izopropanol, n-butanol, t-butanol, dimetilformamid, dimetilacetamid, N-metil pirolidon, toluen, benzen, ksilen, THF, dioksan, 2-metoksietil-eter, dietil-eter, izopropil-eter, t-butil-metil-eter, etil-acetat, izopropil-acetat, acetonitril i njihove smjese.
A capsule (2) according to any one of the preceding claims, wherein the lid (14) is connected to the flange-like rim (20) and the inner space (22) is at least partially filled with the extractable product. 
Kapsula prema jednom od prethodnih patentnih zahtjeva, pri čemu je poklopac (14) povezan na čašicu na drugom kraju obodnog zida (102), npr.
Mobile phase: 
Mobilna faza: Heksan:
a serving MSC for controlling cells represented by groups of base transceiver stations (BTS) located at fixed geographical locations providing mobility management for mobile stations, and where the assessing of received information in step c) includes to perform a paging procedure on relevant MSISDNs for receiving ids of present serving cells for each relevant MSISDN, and checking whether the returned cell ids are within the range of the cells covering the relevant geographical area. 
- < opslužujućim MSC za nadzor stanica koje su predstavljene sa skupinama baznih primopredajnih stanica (BTS) koje se nalaze na fiksnim geografskim područjima koje osiguravaju upravljanje mobilnošću za mobilne stanice, te gdje procjena informacija primljenih u koraku c) uključuje provođenje postupka jednosmjernog pozivanja prema relevantnim MSISDN-ovima radi prijema identifikatora o trenutnim opslužujućim stanicama za svaki odgovarajući MSISDN, te provjere da li su vraćeni brojevi stanica unutar opsega stanica koje pokrivaju određeno zemljopisno područje.
The system of claim 23 wherein the conduit is made of plastic. 
Sustav prema zahtjevu 23, naznačen time što je cjevovod napravljen od plastike.
The use of a compound of any one of Claims 1 through 9 for the manufacture of a medicament for inducing degradation of a c-kit, Bcr-Abl, FLT3, or EGFR, protein; inhibiting topoisomerase II; or modulating the activity of glucocorticoid receptors. 
Uporaba spoja bilo kojeg od zahtjeva 1 do 9 za proizvodnju lijeka za induciranje degradacije c-set, Bcr-Abl, FLT3, ili EGER, proteina; inhibiranje topoizomeraze II; ili moduliranje aktivnosti glukokortikoid receptora.
The compound of claim 1 wherein R1 is aminomethyl, R2 is hydrogen, R3 is halo, and R4 is halo; or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što R! je aminometil, R je vodik, R* je halogen i R* je halogen, ili njegova farmaceutski prihvatljiva sol.
sending, on the part of a communications device associated with the NFF base station, the subscriber identification data and an amount to be paid to a subscriber server; 
slanja (310), od strane komunikacijskog uređaja (137) povezanog sa navedenom NFF baznom stanicom (115), navedenih identifikacijskih podataka pretplatnika i iznosa koji treba platiti pretplatničkom serveru (150);
Reversal of hyperalgesia in the ipsilateral paw is calculated according to the formula: EPMATHMARKEREP Neuropathic hyperalgesia test 
Kombinacija sukladno patentnom zahtjevu 8 pri čemu ta kombinacija nije fizički povezana kombinacija u obliku:
Acamprosate, or a salt, enantiomer, or racemate thereof, in combination with baclofen, or salt, enantiomer or racemate thereof, for use in the preventive or curative treatment of a brain ischemic or brain hypoxic injury in a subject. 
Baklofen, ili njegova farmaceutski prihvatljiva sol, u kombinaciji s barem akamprozatom, ili njegovom farmaceutski prihvatljivom soli, za uporabu u poboljšanju kognitivnih simptoma u subjekta koji boluje od, ima predispoziciju ili se sumnja da boluje od Alzheimerove bolesti.
In one aspect, a method for making a humanized mouse is provided, comprising replacing mouse exons encoding ectodomain sequences of mouse IL-6Ra with a human genomic fragment encoding ectodomain sequences of human IL-6Ra to form a humanized IL-6Ra gene. 
Postupak za stvaranje humaniziranog miša, naznačen time da sadrži zamjenu svih mišjih eksona koji kodiraju sekvence ektodomene za mišji IL-6Ra sa ljudskim genomskim fragmentom koji kodira ljudsku ektodomenu IL- 6Ra da se dobije humanizirani IL-6Ra gen, pri čemu je humanizirani IL-6Ra.
The process of claim 2, wherein the carbon tetrachloride is present in an amount up to about 50 weight percent of the reaction mixture. 
Postupak iz patentnog zahtjeva 2, pri čemu je ugljikov tetraklorid prisutan u količini do 50 težinskih postotnih udjela reakcijske smjese.
A process according to claim 1, wherein the solid material is a pharmaceutically active ingredient selected from the group consisting of anti-allergics, bronchodilators, anti-inflammatory steroids and mixtures thereof. 
Postupak u skladu s bilo kojim prethodnim patentnim zahtjevom, pri čemu je čvrsti materijal farmaceutski aktivan sastojak odabran iz grupe koja se sastoji od antialergika, bronhodilatatora, protuupalnih steroida i njihovih smjesa.
The method according to claim 3, wherein an active substance of the formula III, in which 
Postupak prema patentnom zahtjevu 3, naznačen time što se koristi aktivna supstanca formule III,
This concerns the compounds of the following formula: 
Datum objave europske prijave patenta:
deprotecting a compound of Formula XXVII to give a compound of Formula XXVIII 
[image] sa spojem Formule IX: -H Formula IX čime se dobiva spoj Formule XXVII:
In some embodiments, the low conductivity dilution buffer has a conductivity less than the conductivity of a 150 mM sodium chloride solution, less than the conductivity of a 120 mM sodium chloride solution, less than the conductivity of a 90 mM sodium chloride solution, less than the conductivity of a 60 mM sodium chloride solution, less than the conductivity of a 40 mM sodium chloride solution, or less than the conductivity of a 20 mM sodium chloride solution. 
Postupak u skladu s patentnim zahtjevom 13, naznačen time što niskovodljivi pufer za ispiranje ima vodljivost nižu od vodljivosti 150 mM otopine natrijevog klorida, nižu od vodljivosti 120 mM otopine natrijevog klorida, nižu od vodljivosti 99 mM otopine natrijevog klorida, nižu od vodljivosti 60 mM otopine natrijevog klorida, nižu od vodljivosti 40 mM otopine natrijevog klorida, ili nižu od vodljivosti 20 mM otopine natrijevog klorida.
Coating was carried out under the following conditions: 
Prevlačenje je izvršeno u sljedećim uvjetima:
pyrazolyl cationally substituted with one or more substituents selected from the group consisting of C1-6-alkyl optionally substituted with halogen, or C1-6-alkoxy; cyclo C3-8-alkyl; halogen; phenyl optionally substituted with C1-6-alkoxy; furyl and thienyl; 
pirazolil po želji supstituiran s jednim ili više supstituenata odabranih iz skupine koja sadrži sljedeće: C1-6-alkil po želji supstituiran s halogenom, ili C1-6-alkoksi; ciklo-C3-8-alkil; halogen; fenil po želji supstituiran s C1-6-alkoksi; furil i tienil;
insoluble whey protein particles having a particle size in the range of 1-10 micron, where the amount of said insoluble whey protein particles is in the range of 50-100% (w/w) relative to the total amount of the denatured whey protein composition, a fruit flavouring agent, and food acid 
gdje netopljive čestice proteina sirutke imaju veličinu čestica u rasponu od 1-10 um, gdje je količina netopljivih čestica navedenog proteina sirutke u rasponu od 50-100 % (tež./tež.) u odnosu na 5 ukupnu količinu pripravka denaturiranog proteina sirutke, - = sredstvo za davanje voćne arome, i -
A maleate salt of 4-((4-fluoro-2-methyl-1 H -indol-S-yl)oxy)-6-methoxy-7-(3-(pyrrolidan-1-yl)propoxy)quinazoline, in the crystalline form Form A, according to claim 1 wherein said salt has an X-ray powder diffraction pattern with specific peaks at 2-theta - 21.5, 16.4, 24.4, 20.7, 25.0, 16.9, 12.1, 22.2, 17.4 and 17.6° wherein said values may be plus or minus 0.5° 2-theta. 
Maleatna sol 4-((4-fluoro-2-metil-12-indol-S-il)oksi)-6-metoksi-7-(3-(pirolidan-1-il)propoksi)kinazolina, u kristalnoj Formi A, prema zahtjevu 1, naznačena time, da navedena sol ima uzorak difrakcije X-zraka na puderu sa specifičnim vršcima kod 2-theta - 21.5, 16.4, 24.4, 20.7, 25.0, 16.9, 12.1, 22.2, 17.41 17.6" pri čemu navedene vrijednosti mogu varirati plus ili minus 0.5 2-theta.
A compound of formula I, or a salt thereof, for use in the treatment of a disease or condition comprising inhibiting inflammation, wherein formula I is: wherein n is 1; 
Spoj formule I, ili njegova sol, namijenjen upotrebi u liječenju bolesti ili stanja koje se sastoji u inhibiranju upale, gdje formula I je: HR P20110779 TI Sah
cardiac arrhythmia. The pharmaceutical composition of claim 3, wherein said pharmaceutical composition is formulated for treating a condition selected from the group consisting of: 
(b) instrukcija za uporabu farmaceutskog pripravka iz (a) za liječenje stanja koje je odabrano iz skupine koju čine:
Package according to anyone of claims 11 to 13, characterised in that the front wall (40) of the inner shell (6; 96; 106, 107) comprises a reinforced structure, preferably made from double-layer or triple-layer cardboard (40, 76). 
Omot za pakiranje u skladu s bilo kojim od patentnih zahtjeva 14 do 16, naznačen time što prednja stijenka (40; 128) unutarnje ljuske (6; 96; 106, 107; 116) ima pojačanu strukturu, poželjno načinjenu od dvostrukog sloja ili trostrukog sloja kartona (40; 76).
Machine according to claim 4, characterized in that the milling means are comprised of a plurality of cutting mills (15, 16) adapted to rotate about respective vertical axes (24, 25). 
Stroj prema zahijevu 4, naznačen time da se sredstva za rezanje sastoje od mnoštva noževa za rezanje (15, 16) koji su prilagođeni da rotiraju oko odgovarajućih okomitih osi (24, 25).
determining a GLP-1 level in a blood or plasma sample obtained from a mammal, the mammal having been administered with a GPR119 agonist, wherein the ability of the GPR119 agonist to increase a GLP-1 level in the blood or plasma sample obtained from the mammal is indicative of the agonist being a GLP-1 secretagogue; and 
(a) određivanje nivoa GLP-I u krvi u biološkom uzorku dobivenom iz sisavca, pri čemu je navedenom sisavcu bio primjenjen GPR119 agonist; pri čemu je sposobnost GPR119 agonista da poveća nivo GLP-1 u krvi u sisavcu indikativna da je agonist GLP-I sekretogog.
• MAGE-C2, wherein any combination of these antigens is possible. 
MAGE-C2, pri čemu je moguća bilo koja kombinacija ovih antigena.
which is optionally further substituted by one, two or three substituents X, whereby each X is selected from the group consisting of halogen, oxo, -C1-4-alkyl, -O-C1-4-alkyl, -C1-4-haloalkyl, -O-(C1-4-alkylene)- Het, Het, Hetaryl, -NH2, 
C1-4-alkil, -O-C1-4-alkil, -C1-4-haloalkil, -O-(C1-4-alkilen)-Het, Het, Hetaril, -NH2, pri čemu je supstituent X opcionalno dalje supstituiran s jednim, dva ili tri supstituenta iz skupine odabrane od okso, metila, etila, n-propila, izopropila, n-butila, izobutila i tert-butila, ili gdje R1 is
The method of claim 1, wherein said selecting is based on ceramide level in lung epithelium, nasal epithelium, mucus, and/or cells isolated from an open wound site. 
Kisela ceramidaza za uporabu prema zahtjevu 1, naznačena time što se navedeni odabir temelji na razini ceramida u plućnom epitelu, nazalnom epitelu, sluzi i / ili stanicama izoliranim sa mjesta otvorene rane.
Emb-4: The use according to Emb-3, where dose a is within the range of from 10 to 65 wt.-% of dose c and where dose b is within the range of from 35 to 90 wt.-% of dose c. 
Tapentadol prema patentnom zahtjevu 4, naznačen time da je doza a unutar raspona od 10 do 65 % po težini doze o i da je doza b unutar raspona od 35 do 90 % po težini doze c.
The term "overage" means for the purposes of the present invention the amount of opioid analgesic contained in a transdermal delivery device that is not delivered to the patient. 
Uređaj za transdermalnu dostavu prema patentnom zahtjevu 1, naznačen time da je količina antagonista u pojedinoj mikrosferi od 5 % do 70 % po težini.
at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 4,000,000 and 
(po težini) polietilen oksida koji sadrži, bazirano na reološkim mjerenjima, približnu molekulsku težinu od barem
is hydrogen, hydroxy, unsubstituted alkylamino, unsubstituted alkoxy or amino; 
Rz je vodik, hidroksi, nesupstituirani alkilamino, nesupstituirani alkoksi ili amino;
The method of claim 7, further comprising: determining the female subject to also have the deletion in the first subchromosomal region when the count classification indicates the deletion and the size classification indicates the aberration does not exist in the first subchromosomal region, or 
utvrđivanja da kod ispitanice također dolazi do delecije u prvoj subkromosomskoj regiji kada klasifikacija broja ukazuje na deleciju, a klasifikacija veličine ukazuje da delecija ne postoji u prvoj subkromosomskoj regiji, ili utvrđivanja da kod ispitanice ne dolazi do delecije u prvoj subkromosomskoj regiji kada klasifikacija broja ukazuje na deleciju i klasifikacija veličine ukazuje na deleciju.
The use of claim 1 or 4, or the antibody or fragment for use according to claim 1 or 4, wherein said anti-CD44 antibody comprises a VH domain having the amino acid sequence of SEQ ID NO:9 or SEQ ID NO: 10. 
Uporaba prema zahtjevu 1 ili 4, ili protutijelo ili fragment za uporabu prema zahtjevu 1 ili 4, naznačena time, da navedeno protutijelo anti-CD44 sadrži VH domenu koja ima aminokiselinsku sekvencu SEQ ID NO:9 ili SEQ ID NO:10.
a compound represented by: or a pharmaceutically acceptable salt thereof; and 
ili njegova farmaceutski prihvatljiva sol, stereoizomer, 1/ili N-oksid.
In preferred embodiments, the third polymeric material is an at least partially, preferably fully, neutralised co-polymer of (meth)acrylic acid and a (meth)acrylic acid C1-4 alkyl ester. 
Formulacija lijeka s produljenim oslobađanjem za koju se traži zaštita patentom u bilo kojem od prethodnih patentnih zahtjeva, pri čemu je treći polimerni materijal bar djelomično neutraliziran kopolimera (met)akrilne kiseline i (met)akrilna kiselina C1-4 alkil ester.
A pharmaceutical composition comprising an oligonucleotide decoy of any one of claims 1 to 4 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća oligonukleotidnu zamku prema bilo kojem od zahtjeva 1 do 41 farmaceutski prihvatljiv nosač.
A process according to any preceding claim, wherein the unfermented organic material is processed into a cake after separation from the stillage. 
Postupak prema bilo kojem prethodnom zahtjevu, naznačen time da se nefermentirani organski materijal obrađuje u kolač nakon odvajanja iz silaže.
In some embodiments, the second dosage composition can comprise a time delay agent. The time delay agent can be one of sodium alginate, glyceryl monostearate, glyceryl distearate, forms of acrylic acids, forms of celluloses or combinations thereof. 
Kapsula u skladu s patentnim zahtjevom 6, naznačena time što se tvar koja odgađa otpuštanje sastoji od natrijeva alginata, gliceril monostearata, gliceril distearata, akrilnih kiselina, celuloza ili kombinacija navedenog.
The material according to any of claims 1 to 12, which is expanded to a density of less than 80 kg/m3, preferably less than 60 kg/m3, especially preferred less than 50 kg/m3 according to DIN EN ISO 845. 
Materijal prema bilo kojem od patentnih zahtjeva od 1 do 11 naznačen time da je ekspandiran do gustoće manje od 80 kg/m3, poželjno manje od 60 kg/m3, naročito poželjno manje od 50 kg/m3 u skladu s DIN EN ISO 845.
and R3 represent hydrogen; 
Ri R" predstavljaju vodik;
A compound for use according to claim 15, wherein said diseases are selected in the group including asthma, emphysema and chronic obstructive pulmonary disorders. 
Spoj za uporabu prema zahtjevu 15, naznačen time da su navedeno bolesti odabrane iz skupine koja uključuje astmu, emfizem i kronične opstruktivne plućne poremećaje.
A developer supply container according to claim 18, wherein the nozzle portion is provided with a plurality of openings around a free end side of the nozzle portion. 
Spremnik za nadopunjavanje razvijača u skladu s patentnim zahtjevom 19, naznačen time što navedena mlaznica (47) ima više otvora (51) oko svoje strane sa slobodnim krajem.
a vacuum chamber having an input end for introduction of a container for the organic material into the vacuum chamber and a discharge end for removal of the container; 
vakuumsku komoru (22) koja ima ulazni kraj (30) za uvođenje posude (38) za organski materijal u vakuumsku komoru i kraj (24) za pražnjenje za uklanjanje posude;
The aqueous pharmaceutical suspension according to claim 3, wherein the sucrose or invert sucrose is, by weight/volume (g/100 mL), 10% to 40%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što saharoza ili invertna saharoza iznosi, težinski/volumno (g/100 ml), otprilike 10 % do otprilike 40 %.
In some embodiments, the cancer is selected from the group consisting of small cell lung cancer, neuroblastomas, melanoma, breast carcinoma, gastric cancer, colorectal cancer (CRC), and hepatocellular carcinoma. 
Anti-Notch1-NRR-protutijelo za uporabu prema zahtjevu 17, naznačeno time, da poremećaj je rak, tumor, i/ili poremećaj proliferacije stanice odabran iz skupine koju čine kolorektalni rak, gastrointestinalni rak, rak pluća, rak dojke, rak jajnika, akutna limfoblastična leukemija T-stanica (T-ALL) i melanom.
The disposable grill according to claim 1, wherein said at least one thermal insulating insert is adapted to fit said bottom part inside said base tray. 
Roštilj (1) za jednokratnu uporabu prema zahtjevu 1, gdje je najmanje jedan navedeni termo-izolacijski uložak (7) prilagođen da stane u navedeni donji dio (3) unutar navedene osnovne posude (2).
Apparatus according to claim 3, wherein the plurality of anvils may be provided as a pair of anvils on either of the mounting members and an intermediate third roller on the other of the mounting members. 
Uređaj prema zahtjevu 3, gdje postoji niz nakovanja kao parovi nakovanja na bilo kojem od ugradbenih članova i srednji treći valjak na drugom od ugradbenih članova.
1991) and the adhesion molecule VCAM has 7 Ig-like domains (Osborn et al. 
1991), a adhezivna molekula VCAM ima 7 Ig-sličnih domena (Osborn 1 sur.
to induce a conformational change in the HER3 receptor to an active state; or 
inducirati konformacijsku promjenu u HER3-receptoru na aktivno stanje; ili
calculating from the varying torque and the obtained rotational top end drive speed an estimated torque-speed transfer function, 
- izračunavanja (54) procijenjene funkcije prijenosa okretnog momenta u brzinu iz navedenog promjenjivog okretnog momenta i navedene dobivene vršne brzine vrtnje pogona;
the first antibody H chain consists of SEQ ID NO: 20; 
(a14) H-lanac protutijela koji se sastoji od aminokiselinske sekvence SEQ ID NO: 20;
The composition for use according to claim 4, wherein the crystalline structure (R)-PG is characterized by one or more of the following: 
Kristalna struktura kako je definirano u zahtjevu 6 naznačena time da ima jedno ili više od slijedećeg: